Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Related Keywords

California ,United States ,Canada ,France ,America ,Benitec Biopharma ,William Windham ,Central Ethics Committee ,Clinical Development Program Overview ,Benitec Biopharma Inc ,Nasdaq ,Solebury Strategic Communications ,Exchange Commission ,Regulatory Updates For The Clinical Development Program ,Research Ethics Board ,Assay Method Development ,Fiscal Year ,Executive Chairman ,Chief Executive Officer ,Oculopharyngeal Muscular Dystrophy ,Development Program Overview ,Pharyngeal Residue ,Maximum Constriction ,Imaging Grade ,Swallowing Toxicity Scale ,Pyriform Sinus Residue ,Residue Ratio Scale ,Construction Ratio ,Treatment Study ,Regulatory Updates ,Clinical Development Program ,Second Calendar Quarter ,Patient Informed Consent Form ,Principal Investigators ,Third Calendar Quarter ,Patient Informed Consent ,Fourth Calendar Quarter ,Institutional Review Board ,Trial Application ,Investigational New Drug ,First Calendar Quarter ,Toxicology Study ,Parallel Assay Method Development ,Comprehensive Loss ,Ended June ,Relations Contact ,Covid 19 ,Science ,Technology ,Health ,Muscular Dystrophy ,Biotechnology ,Hayward ,Business ,Globe Newswire ,Gene Therapy ,